SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950123-09-057719
Filing Date
2009-11-04
Accepted
2009-11-04 17:29:44
Documents
7
Period of Report
2009-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q b77436e10vq.htm 10-Q 543983
2 EX-10.1 LETTER AGREEMENT BETWEEN THE REGISTRANT AND JOHN A. SCHMIDT, JR., M.D. b77436exv10w1.htm EX-10.1 37037
3 EX-31.1 SECTION 302 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER b77436exv31w1.htm EX-31.1 8366
4 EX-31.2 SECTION 302 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER b77436exv31w2.htm EX-31.2 8369
5 EX-32.1 SECTION 906 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER b77436exv32w1.htm EX-32.1 3404
6 EX-32.2 SECTION 906 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER b77436exv32w2.htm EX-32.2 3458
7 GRAPHIC b77436b7743600.gif GRAPHIC 9949
  Complete submission text file 0000950123-09-057719.txt   619940
Mailing Address 300 THIRD STREET CAMBRIDGE MA 02142
Business Address 300 THIRD STREET CAMBRIDGE MA 02142 (617) 551-8200
ALNYLAM PHARMACEUTICALS, INC. (Filer) CIK: 0001178670 (see all company filings)

IRS No.: 770602661 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-50743 | Film No.: 091158766
SIC: 2834 Pharmaceutical Preparations